ClinicalTrials.gg

Program

BI 1584862

A development code. Also written as “[13C]-labeled BI 1584862”.

In Boehringer Ingelheim's pipeline, Phospholipid modulator. Its studies are mostly in Geographic Atrophy · Hepatic Insufficiency, led by Boehringer Ingelheim.

Furthest: phase 2, since Jan 7, 20257 company-led studies, 1 open or runningNext primary completion: Dec 22, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim71 open or runningphase 2since Jan 7, 2025Aug 29, 2022Dec 22, 2026phase 2 · NCT06769048
  • Named in Boehringer Ingelheim’s own pipeline as BI 1584862, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2022First study: phase 1 study in HealthyFirst studyNCT05520827 · 77 enrolled · Germany
  2. Aug 17, 2023Phase 1 study in HealthyNCT06006598 · 50 enrolled · Germany
  3. Sep 12, 2023Phase 1 study in HealthyNCT06041438 · 14 enrolled · Germany
  4. Nov 20, 2023Phase 1 study in HealthyNCT06148948 · 32 enrolled · Japan
  5. Jan 7, 2025Phase 2 study in Geographic AtrophyNCT06769048 · 150 enrolled · United States, Puerto Rico
  6. May 2, 2025Phase 1 study in Hepatic InsufficiencyNCT06957756 · 43 enrolled · United States
  7. Jan 2, 2026Phase 1 study in HealthyNCT07336758 · 8 enrolled · Netherlands

Ahead

  1. Dec 22, 2026Primary completion: phase 2 study in Geographic AtrophyNCT06769048

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Phospholipid modulator”the company's pipeline, read by Claude · source

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07336758Healthy · Netherlands1CompletedMar 4, 20268
NCT06957756Hepatic Insufficiency · United States1CompletedMay 21, 202643
NCT06769048Geographic Atrophy · United States, Puerto Rico2Active, not recruitingDec 22, 2026150
NCT06148948Healthy · Japan1CompletedMay 21, 202432
NCT06041438Healthy · Germany1CompletedNov 10, 202314
NCT06006598Healthy · Germany1CompletedMay 5, 202450
NCT05520827Healthy · Germany1CompletedMar 6, 202377

How it is read

Names in the registry

  • “BI 1584862”, 6 entries
  • “[13C]-labeled BI 1584862”, 1 entry

Codes read as this program: BI1584862.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
BI 1584862 (Boehringer Ingelheim): development program | ClinicalTrials.gg